Suchergebnisse - "Alberti, Paola"

PubPharm (8)

1

Neurofilament light chain : a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity

enthalten in: Archives of toxicology | 2020

von Meregalli, C. | Fumagalli, G. | Alberti, P. | +9

2

Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity

enthalten in: Archives of toxicology | 2020

von Meregalli, C. | Fumagalli, G. | Alberti, P. | +9

3

Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity

enthalten in: Archives of toxicology | 2020

von Meregalli, C. | Fumagalli, G. | Alberti, P. | +9

4

Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity

enthalten in: Archives of toxicology | 2020

von Meregalli, C. | Fumagalli, G. | Alberti, P. | +9

5

Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy

enthalten in: Experimental neurology | 2020

von Bruna, J. | Alberti, P. | Calls-Cobos, A. | +3

6

Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy : A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial

enthalten in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics | 2018

von Bruna, J. | Videla, S. | Argyriou, A. | +13

7

Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial

enthalten in: Neurotherapeutics | 2017

von Bruna, J. | Videla, S. | Argyriou, A. | +13

8

Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial

enthalten in: Neurotherapeutics | 2017

von Bruna, J. | Videla, S. | Argyriou, A. | +13

1
[1]